Recent Company News

• 04:55 PM ET Jun 07, 2026
  

  Amgen présente de nouvelles données lors des 86e Sessions Scientifiques de l’American Diabetes Association (ADA), incluant les résultats de sous-groupes de l’étude de phase 3 VESALIUS-CV ($349.58, 0.00)

• 04:55 PM ET Jun 07, 2026
  

  Amgen presents new data at the American Diabetes Association (ADA) 86th Scientific Sessions including Phase 3 VESALIUS-CV subgroup results ($349.58, 0.00)

• 02:45 AM ET May 29, 2026
  

  Aspen Pharmacare Holdings completes the divestment of Aspen APAC (ZAR 134.75, 0.00)

• 10:37 AM ET Apr 27, 2026
  

  StreetAccount M&A Summary: Week of 20-Apr

• 07:20 AM ET Apr 21, 2026
  

  Aspen Pharmacare Holdings shareholders approve the sale of Aspen APAC (ZAR 129.93, +0.72)

• 04:58 PM ET Mar 28, 2026
  

  Amgen announces Repatha cuts risk of first major cardiovascular events by 31% in high-risk patients without known significant atherosclerosis ($348.77, 0.00)

• 01:08 AM ET Mar 09, 2026
  

  Aspen Pharmacare Holdings upgraded to buy from hold at HSBC (ZAR 138.03, 0.00)

• 02:30 AM ET Mar 04, 2026
  

  Transcript Intelligence: Aspen Pharmacare Holdings Q2 Earnings Guidance

• 02:30 AM ET Mar 04, 2026
  

  Transcript Intelligence: Aspen Pharmacare Holdings Q2 Earnings Themes

• 02:30 AM ET Mar 04, 2026
  

  Transcript Intelligence: Aspen Pharmacare Holdings Q2 Earnings Q&A